50
Participants
Start Date
August 24, 2023
Primary Completion Date
April 21, 2026
Study Completion Date
April 21, 2026
EGCG 300 mg + Nintedanib
"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
EGCG 300 mg + Pirfenidone
"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
Placebo 2 capsules + Nintedanib or Pirfenidone
"Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
EGCG 600 mg + Nintedanib
"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
EGCG 600 mg + Pirfenidone
"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
Placebo 4 capsules + Nintedanib or Pirfenidone
"Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
RECRUITING
Weill Cornell Medicine, New York
RECRUITING
Temple University, Philadelphia
NOT_YET_RECRUITING
University of Virginia, Charlottesville
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
UCSF Parnassus, San Francisco
RECRUITING
University of Washington, Seattle
RECRUITING
Massachusetts General Hospital, Boston
Collaborators (1)
University of Michigan
OTHER
Cornell University
OTHER
Massachusetts General Hospital
OTHER
Temple University
OTHER
University of Washington
OTHER
University of Virginia
OTHER
Hal Chapman
OTHER